CytoDyn (OTCQB: CYDY) is a biotechnology company developing innovative treatments for multiple therapeutic indications based on PRO 140 (leronlimab), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor is also implicated in tumor metastasis and in … Continue reading “CytoDyn Inc. (CYDY) Starts Presentation at 9th Annual LD Micro Invitational”
Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced the appointment of David F. Welch, Ph.D., Founder, Chief Innovation Officer and Director of Infinera Corporation, to the CytoDyn Board of Directors. Dr. Welch has a notable background including strategic planning expertise and broad capital markets experience. As an investor in the company, he appreciates the potential … Continue reading “NetworkNewsBreaks – CytoDyn Inc. (CYDY) Appoints New Member to Board of Directors”
Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced that it will be presenting at the Biotech Showcase at the Hilton San Francisco Union Square in San Francisco, California on January 9, 2019 at 10:30 AM PT. An update on the company’s clinical development programs and objectives for leronlimab (PRO 140) will be co-presented by president … Continue reading “NetworkNewsBreaks – CytoDyn Inc. (CYDY) to Present at Biotech Showcase Conference”
Biotechnology company CytoDyn (OTCQB: CYDY) today announced the election of its Chief Medical Officer and Director Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P. to the additional position of vice chairman of the board of directors. In this added role Pestell, an internationally renowned clinician and cancer researcher and defining force in CCR5 antagonist research, … Continue reading “NetworkNewsBreaks – CytoDyn Inc. (CYDY) Names Richard G. Pestell, M.D., Ph.D. as Board Vice Chairman, Expanding Leadership Role in Advancement of Company Initiatives”
Biotechnology company CytoDyn (OTCQB: CYDY) anticipates that it will attain final FDA approval for its HIV treatment, PRO 140, by the fourth quarter of 2019. The company expects market availability will follow by 2020. An article further discussing the company reads, “Leronlimab (PRO 140) is part of a new class of HIV drugs that protects … Continue reading “NetworkNewsBreaks – CytoDyn Inc. (CYDY) Foresees Market Availability of PRO 140 by 2020”
Biotechnology company CytoDyn (OTCQB: CYDY) today announced that it has named Nitya G. Ray, Ph.D. to serve as its new chief technology officer – head of process sciences, manufacturing & supply chain. Dr. Ray, from November 2015 to June 2017, served as CytoDyn’s senior vice president of manufacturing. Most recently, he served Actinium Pharmaceuticals, Inc. … Continue reading “NetworkNewsBreaks – CytoDyn Inc. (CYDY) Appoints Chief Technology Officer Nitya G. Ray, Ph.D.”
Biotechnology company CytoDyn (OTCQB: CYDY) today announced that its board of directors has appointed Scott A. Kelly, M.D., FAAPMR as its chairman. Dr. Kelly has served on CytoDyn’s board since April 2017, and he succeeds Anthony D. Caracciolo, who will continue to serve as a company director. “We are delighted to have Scott serve as … Continue reading “NetworkNewsBreaks – CytoDyn Inc. (CYDY) Appoints Dr. Scott Kelly as Chairman of the Board”
PRO 140 has FDA fast track designation that allows accelerated approval The drug protects healthy cells from HIV infection by binding to CCR5 cellular co-receptor Market for PRO 140 as a single agent therapy projected at about $4 billion annually CYDY recently initiated its first cancer trial in triple negative breast cancer, targeting an unmet … Continue reading “CytoDyn, Inc. (CYDY) Expects FDA Approval for PRO 140 in HIV by Q4 2019, $500M Revenue Forecast for 2020”
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced that President and CEO Nader Pourhassan, Ph.D., and Chief Medical Officer Richard Pestell, M.D., Ph.D., F.A.C.P., M.B.A., will host an investment community conference call on Wednesday, December 12, at 4:00 p.m. ET. To access the call, interested parties should dial 877-407-2986 (U.S. and Canada) or 201-378-4916 … Continue reading “NetworkNewsBreaks – CytoDyn Inc. (CYDY) to Host Conference Call, Provide Business Update on December 12, 2018”
CytoDyn, Inc. (OTC: CYDY) is a biotechnology company developing innovative treatments for multiple therapeutic indications based on PRO 140 (leronlimab), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor is also implicated in tumor metastasis and … Continue reading “CytoDyn, Inc. (CYDY) Starts Presentation at LD Micro Main Event”
